A portfolio of patents, based on the use of stem cell treatments for neurological disorders and cancer, has been acquired by the SanBio group, as reported in Businesswire.com
The technology underpinning the patent portfolio is based on enhancing anti-inflammatory and pro-inflammatory functions of mesenchymal stem cells (MSC’s) and was discovered by Tulane University researcher Dr. Aline Betancourt.
The technology has the potential to provide therapeutic treatments for neurological disorders such as multiple sclerosis, diabetic neuropathy and inflammatory disorders (using the MSC2 phenotype), whereas the MSC1 phenotype has been associated with slowing down and reducing the growth of tumours, which has generated interest in the technology as a potential cancer treatment.
The acquisition enables SanBio to continue and expand its development for treatments of inflammatory disorders and cancer.
Grace Century President and Director of Research Scott Wolf comments “One of the most frustrating parts about dealing with new breakthroughs, is how long they take to get the necessary support to grow to fruition. The main push back from investors and consumers alike is the lack of treatments available today using stem cells, specifically the MSC type found in dental pulp and bone marrow. Reports like this shows how close we might be to treatments in anti-inflammatory cases, and even cases of cancer treatment are underway”.
